COMPANY PROFILE

Ambagon Therapeutics

Explore full profile

Biotechnology company developing small molecule drugs that target previously undruggable proteins for cancer treatment

Eindhoven, NetherlandsFounded 2020Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Ambagon Therapeutics

Ambagon Therapeutics is a biotechnology startup focused on expanding the druggable proteome by targeting intrinsically disordered proteins (IDPs), a class of proteins that have historically been considered undruggable. The company has developed a proprietary platform designed to create novel medicines capable of interacting with these challenging targets. By enabling therapeutic intervention at previously inaccessible sites within the proteome, Ambagon aims to address diseases that have eluded traditional drug discovery approaches. The company's scientific strategy centers on overcoming the limitations of conventional small molecule drugs, opening new avenues for treating complex conditions linked to IDPs.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Eindhoven, Netherlands
Employees: 16
Open positions: None listed
Dealroom signal: 67.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Molecular Biology, Molecular, Spinout, Tech for Biotech and Pharma, Biotech and Pharma, Small Molecules
Business model: Manufacturing, SaaS
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Feb 2025	$5M	$425M	Undisclosed	↗
SERIES AOther financing	Jan 2022	$85M	$340M	Abbvie Biotech Ventures · RA Capital Management · Droia Oncology Ventures · Inkef	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Ambagon Therapeutics website traffic

Latest recorded traffic for Ambagon Therapeutics is 570 monthly website visits, down 43% over the last three months. Ambagon Therapeutics's team declined 5.9% over the past year.

Latest monthly visits570 3-month web change-43% 1-year team growth-5.9%

Monthly website visitsApr 2021–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational	44	$217M	$700M
ATAmphista TherapeuticsNext-generation therapeutics for targeted protein degradation	Great Abington, United Kingdom	Operational
PEPeptomycFoundational anti-MYC mini-proteins for cancer treatment	Barcelona, Spain	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
SBSibylla BiotechFacing the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs	Bresso, Italy	Operational
ILiLoFAI and photonics platform for personalized drug discovery.	London, United Kingdom	Operational
RTRepare TherapeuticsDevelops precision cancer therapies using synthetic lethality and CRISPR-based discovery platforms	Montreal, Canada	Acquired
NENeurocentrxOral ketamine formulations for treatment-resistant mood disorders	Edinburgh, United Kingdom	Operational